| Literature DB >> 29774281 |
Ernest Tambo1,2, Christopher Khayeka-Wandabwa3,4, Oluwasogo A Olalubi5, Ahmed A Adedeji6, Jeanne Y Ngogang1,7, Emad Im Khater8,9.
Abstract
Globalization, with consequent increased travel and trade, rapid urbanization and growing weather variation events due to climate change has contributed to the recent unprecedented Zika virus (ZIKV) pandemic. This has emphasized the pressing need for local, national, regional and global community collaborative proactiveness, leadership and financial investment resilience in research and development. This paper addresses the potential knowledge gaps and impact of early detection and monitoring approaches on ZIKV epidemics and related arboviral infections steered towards effective prevention and smart response strategies. We advocate for the development and validation of robust field and point of care diagnostic tools that are more sensitive, specific and cost effective for use in ZIKV epidemics and routine pathophysiology surveillance and monitoring systems as an imperative avenue in understanding Zika-related and other arbovirus trends and apply genomic and proteomic characterisation approaches in guiding annotation efforts in order to design and implement public health burden mitigation and adaptation strategies.Entities:
Keywords: Arbovirus; Diagnosis; Epidemics; Molecular; Pathogenesis; Surveillance; Zika virus
Year: 2017 PMID: 29774281 PMCID: PMC5952677 DOI: 10.1016/j.parepi.2017.01.001
Source DB: PubMed Journal: Parasite Epidemiol Control ISSN: 2405-6731
Fig. 1Summary literature search on immunity and arbovirus worldwide.
General Key characteristics and information on Zika and other (arthropod-borne) arboviral diseases worldwide.
| Arbovirus Disease | Arthropod vector | Arthropod Virus subtype | Incubation period, days | Complications symptoms | Region Epidemics, year(s) | Incidence | Prevalence | Fatality rate |
|---|---|---|---|---|---|---|---|---|
| Zika viral fever | Zika virus (ZKV1,2,3) | 3–7 | Conjunctivitis and joint pain, mother to the baby during pregnancy with microcephaly neurologic and birth defects, Guillain–Barré syndrome syndrome and other poor birth outcomes of babies | Africa, Southeast Asia and the Pacific Islands, 1954, | -NA | 1.5 million | NA | |
| Dengue hemorrhagic fever | Dengue virus (DENV1,2,3,4) | 2–14 | Shock, internal bleeding, and organ damage | Tropical and subtropical regions 1800s, | < 284–528 million infections annually | > 652,212 DHF | < 1% with treatment, 1–5% without; about 25% severe cases | |
| Chikungunya fever | Chikungunya virus | 3–7 | Severe and disabling, Joint and muscle pain, joint swelling, or rash | Africa, Asia, Europe, and the Pacific islands, The Americas on islands in the Caribbean | NA | NA | ||
| Rift valley Fever | Rift valley virus | 2–6 | Hemorrhagic fever, meningo-encephalitis | Eastern, Southern, and Western Africa | NA | NA | 1% in humans; in pregnant livestock, 100% fetus fatality rate | |
| West Nile fever | West Nile virus | 2–15 | Swollen lymph nodes, meningitis, encephalitis, acute flaccid paralysis | North America, Europe, West and Central Asia, Oceania, and Africa, 1937 | NA | NA | 3–15% in severe cases | |
| Yellow Fever | YF virus | 3–6 | Jaundice, liver damage, recurring fever, gastrointestinal bleeding, | Tropical and subtropical regions of South America and Africa, 1937 | NA | NA | 3% in general; 20% chronic cases | |
| Japanese encephalitis disease | Japanese encephalitis virus | 5–15 | Encephalitis, seizures, paralysis, coma, and long-term brain damage | Southeast and East Asia | NA | NA | 20–30% in encephalitis cases |
Key molecular and serological assessment approaches and techniques in Zika and other arboviral infections
Serological and molecular approaches for Zika and arboviruses post infection and unique observations | |||
|---|---|---|---|
| Arbovirus type, sample size of people screened (n) and infection context | Molecular and/or Serology marker assays performed | Window period within which the marker was detected | Unique observations |
| Zika Virus ( | MAC/ELISA for IgM and capture ELISA for IgG with whole viral antigen and monoclonal antibodies. | IgM-3 days after onset of symptoms. IgG-appear after day 10. | Rapid laboratory assay suggested that a dengue virus (DENV1-4) was the causative agent. |
| Zika virus ( | Investigations at this time showed a total leukocyte count of 3.6 × 109 cells/L (reference range = 4.0–11.0 × 109 cells/L), a hemoglobin level of 137 g/L (reference range = 115–150 g/L), a hematocrit of 39%, and platelet count of 230 × 109 cells/L (reference range = 140–400 × 109 cells/L). Reactive lymphocytes were present on a blood film while baseline liver and renal function test results were normal. | Examination on day 5 of illness. | Dengue serologic analysis on day 5 of her illness showed a positive result for IgG, a weakly positive result for IgM, but a negative result for nonstructural protein 1 (NS1 antigen) by enzyme immunoassay. A generic flavivirus group polymerase chain reaction (PCR) result was positive, and the patient was provisionally given a diagnosis of dengue fever. A dengue-specific PCR result was negative. Sequencing of the original flavivirus PCR product identified it as Zika virus (GenBank accession no. |
| Zika virus ( | The man showed leukopenia (4300 cells/L, reference values 4800–10,800/L), monocytosis (15%, reference value 0–12%) and thrombocytopenia (139,000/L reference values 140,000–440,000/L). The woman had a normal full blood count. Transaminases, creatinine, and erythrocyte sedimentation rate were normal in both patients. | 3 days after arrival | In view of the accompanying symptoms and the travel history to French Polynesia during the ongoing ZIKV outbreak, an acute ZIKV infection was suspected. |
| ZIKV–RT-PCR for the female was + ve and − ve for the man | Samples assay at 3 days after return. | Only the female partner was positive confirming the need for more evidence on sexual transmission. | |
| IgG and IgM seroconversion against ZIKV, by indirect immunofluorescence assay | Day 3, 35 and 62 | Indirect immunofluorescence assay (IIFA) and ELISA was positive for dengue (Anti-DENV-IgG & Anti-DENV-IgM) on day 35 while for zika virus, Anti-ZIKV-IgG and Anti-ZIKV-IgM was only positive on IIFA on the same day 35 for the female. IIFA for zika Anti-ZIKV-IgG and Anti-ZIKV-IgM was also positive on day 35 for the man despite the man being –ve of zika virus through ZIKV-RT-PCR. Hence attesting the need to synergize immunoassay with RT-PCR as confirmatory test. | |
| Multiparameter flow cytometry immunological assays-Quantification of leukocyte populations in healthy control samples and Zika patients; mDCs, B cells, T cells, CD4T, CD8T, Naïve CD4, Memory CD4, Naïve CD8 and memory CD8 | convalescent phase | No abnormality in ZIKV patients compared to healthy controls. | |
| Antigen uptake capacity of DCs, using fluorescent FITC-dextran beads as surrogate antigens. | convalescent phase | To determine the functionality of blood DCs in convalescent ZIKV patients compared to healthy controls-The blood DCs from ZIKV patients were established to equally effective for antigen capturing than DCs from healthy donors. This observation is achieved despite the fact that, dendritic cells (DCs) are primary infection targets for most mosquito-borne flaviviruses, | |
| Zika virus ( | ACUTE PHASE-Significant concentration elevation for interleukin (IL)-1b, IL-2, IL-4, IL-6, IL-9, IL-10, IL-13, IL-17, as well as for interferon-γ-induced protein 10 (IP-10), regulated on activation, normal T cell expressed and secreted (RANTES), macrophage inflammatory protein 1 alpha (MIP-1a) and vascular endothelial growth factor (VEGF), when compared to healthy blood donors. | Serum samples were classified as either acute (taken ≤ 10 days after symptom onset) or recovery (taken > 10 days after disease onset). | Interferon-γ (IFN-γ) showed a non-significant increasing pattern in both acute and recovery phase. |
| Acute ZIKV infection ( | 6 days after returning: Laboratory analyses showed: Slightly elevated C-reactive protein level at 5.2 mg/L (reference range < 5.0). Liver function test and complete blood count results were within reference range. An indirect immunofluorescence assay for dengue virus demonstrated an IgG titer of 1:80 and no IgM (cutoff < 1:20). | 6 days after she had returned from a 3-week vacation (within which the clinical symptoms were observed) and subsequent assays to day 11. | Chikungunya virus serology results were negative at day 11. |
a,b(Lanciotti et al., 2008, Charrel et al., 2016, Zammarchi et al., 2015b, Charrel et al., 2016, Kwong et al., 2013, Tappe et al., 2015a, Tappe et al., 2015b, Buathong et al., 2015, Haddow et al., 2012, Pyke et al., 2014, Faye et al., 2013, Zammarchi et al., 2015a, Shinohara et al., 2016, Musso et al., 2015b, Musso et al., 2015c).